Clinical trials: Neuroendocrine Neoplasm
Neuroendocrine Tumors
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors.
- Trial name
- NCT04888481
- Testing
- 68Ga-HA-DOTATATE
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- University of Alberta
Neuroendocrine (NE) Tumors, Metastasis
Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study
When possible, surgery to completely remove small intestinal neuroendocrine tumors (siNETs) is always recommended. However, in cases where the tumor has spread and cannot be cured completely, it is unclear whether a surgical…
- Conditions
- Neuroendocrine (NE) Tumors, Metastasis, Bowel Obstruction
- Trial name
- ENETSSurgSmInt (NCT06787014)
- Testing
- Histopathological review
- Where
- Switzerland
- Volunteers
- 3,200 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Congenital Hyperinsulinism, Neuroblastoma
18F-DOPA II - PET Imaging Optimization
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2.
- Conditions
- Congenital Hyperinsulinism, Neuroblastoma, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04706910
- Testing
- 18F-DOPA, Furosemide Injection
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University of Alberta
Neuroendocrine Neoplasm of Lung, Neuroendocrine Neoplasm of Gastrointestinal Tract (Disorder)
Risk Factors for Neuroendocrine Neoplasms
Recent studies show an increase in neuroendocrine neoplasms, especially for the digestive tract. Previous studies suggest various risk factors that were observed for various tumor sites, e.g.
- Trial name
- NCT06282016
- Testing
- Case-control study (no intervention)
- Where
- Germany
- Volunteers
- 14,250 people, healthy volunteers welcome
- Sponsor
- Bavarian Cancer Registry
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Neuroendocrine Tumors
Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study
The goal of this observational study is to learn about the value of body composition as predictors of pathological grading and prognosis in patients with gastroenteropancreatic neuroendocrine neoplasms.
- Trial name
- GEP-NENs (NCT06983106)
- Testing
- body composition calculate
- Where
- China
- Volunteers
- 633 people
- Sponsor
- Tongji Hospital
Neuroendocrine Tumors
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
The purpose of this study is to see how a new tracer named 18F-MFBG (Meta Fluorobenzyl Guanidine) behaves in the body after injection, how it spreads to all the organs and how it is removed from the body.
- Trial name
- NCT02348749
- Testing
- 18F-MFBG (meta-fluoro benzylguanidine), Positron emission tomography (PET) imaging, Blood draws
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroendocrine Tumors, Small Intestinal NET
Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors
Digestive NETs are the second most common malignant digestive tumor after adenocarcinoma. The most common gastrointestinal NETs arise from the small intestine.
- Conditions
- Neuroendocrine Tumors, Small Intestinal NET, Lymph Node Metastasis
- Trial name
- TEGRELE (NCT05246319)
- Testing
- preoperative imaging
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Laurent BRUNAUD
Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC
ML Decision Model for G-NEC Adjuvant Therapy
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis.
- Conditions
- Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC, Survival Outcomes, Machine Learning
- Trial name
- G-NEC (NCT06663852)
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- Chang-Ming Huang, Prof.
Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
Phase 2 Study of ONC201 in Neuroendocrine Tumors
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in…
- Trial name
- NCT03034200
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter Anderson
Solid Tumor, Clear Cell Renal Cell Carcinoma
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT05199272
- Testing
- 23ME-00610
- Where
- 13 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- 23andMe, Inc.
Neuroendocrine Tumors of the Appendix
Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix
The aim of the present project is to evaluate the frequency of distant metastases and clinically relevant relapse and mortality, respectively, of aNEN (Neuroendocrine Neoplasms of the Appendix) measuring 1 - 2 cm.
- Trial name
- SurvivApp (NCT03852693)
- Testing
- Histopathological review
- Where
- Switzerland
- Volunteers
- 278 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neuroendocrine Neoplasm, China
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy…
- Conditions
- Neuroendocrine Neoplasm, China, Women, Cervical Cancer
- Trial name
- NCT06276309
- Where
- 9 sites in China
- Volunteers
- 300 people
- Sponsor
- Fujian Maternity and Child Health Hospital
Neuroendocrine Tumors
68Ga-DOTA-TATE PET/CT Imaging in NETs
This clinical trial is a pragmatic study aiming to evaluate the innocuity/safety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine…
- Trial name
- NCT04847505
- Testing
- 68Ga-DOTA-TATE
- Where
- 2 sites in Canada
- Volunteers
- 5,000 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Neuroendocrine Tumors
Expanded Access Program of Surufatinib
This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical…
- Trial name
- NCT04814732
- Testing
- Surufatinib
- Where
- 11 sites in United States
- Sponsor
- Hutchmed
Neuroendocrine Tumor, Neuroblastoma
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and…
- Conditions
- Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT05069220
- Testing
- 18F-MFBG, 68Ga-Dotatate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Sarcoma, Ovarian Neoplasm
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm
- Trial name
- AcSé (NCT03012620)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 334 people
- Sponsor
- UNICANCER